HBeAg-negative/ HBeAg-positive / anti-HBeAg/ HBeAg Seroconversion

Entecavir (Baraclude) Produces Greater Decrease in HBV DNA than Adefovir (Hepsera) in Treatment-naive HBeAg+ Patients: 96 Week Data from EARLY Study - 5/06/08

HBeAg and HBV DNA Predict Outcomes of Pegylated Interferon Therapy for Chronic Hepatitis B - 2/19/08

Disease Progression in Patients with HBeAg-negative Chronic Hepatitis B - 1/29/08

Extended Duration Pegylated Interferon Alfa-2a (Pegasys) for Patients with HBeAg Negative Chronic Hepatitis B - 1/11/08

Hepatitis Reactivation Following HBeAg Seroconversion - 12/14/07

Individuals with Hepatitis B Virus Genotype C Experience HBeAg Clearance Later and Less Often - 12/14/07

Gender Difference in the Natural Course of HBeAg-Positive Chronic Hepatitis B - 11/13/07

Entecavir Produces Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in HBeAg-positive Patients - 5/25/07

Lamivudine/Adefovir Significantly Reduces the Development and Progression of Esophageal Varices in HBeAg-negative Patients with Cirrhosis  - 4/17/07

Sustained HBeAg Response Occurs with Both Telbivudine and Lamivudine  - 4/13/07